Investment Rating - The report maintains an "Overweight" rating for the retail industry [1] Core Insights - The 2025 Double Eleven sales period saw a total e-commerce sales of approximately 1,695 billion yuan, representing a year-on-year increase of 14.2%. The comprehensive e-commerce platforms accounted for 1,619.1 billion yuan, with a year-on-year growth of 12.3% [4][9] - Instant retail showed remarkable growth, with sales reaching 67 billion yuan during the Double Eleven period, marking a year-on-year increase of 138% [10][15] - Key product categories such as digital appliances, food and beverages, furniture, and pet products experienced significant growth, with pet sales reaching 9.2 billion yuan, up 59% year-on-year [15][16] Summary by Sections Weekly Industry Viewpoint - The Double Eleven sales period was extended, contributing to steady growth in total e-commerce sales. The sales period for 2025 was from October 7 to November 11, compared to October 14 to November 11 in 2024 [9] - Instant retail emerged as a highlight, with substantial growth compared to traditional e-commerce formats [10] Weekly Market Review - From November 10 to November 16, the Shenwan retail index increased by 4.06%, while the Shanghai Composite Index decreased by 0.18% [17] - Year-to-date performance shows the Shenwan retail index up by 8.43%, compared to a 19.06% increase in the Shanghai Composite Index [17][22] Company Valuation Table - The report includes a detailed valuation table for various companies in the retail sector, with specific metrics such as market capitalization and P/E ratios [24][25]

Core Viewpoint - The company, Aimeike (300896.SZ), confirmed that its acquisition of the South Korean company REGEN is progressing as planned, with the focus on specific medical devices [1]. Group 1 - The company received inquiries from investors regarding the lack of marketing information for its overseas acquisition [1]. - Aimeike stated that REGEN's main products are AestheFill and PowerFill, both classified as Class III medical devices [1]. - The target customer base for these products consists of legitimate medical institutions qualified to use medical devices [1]. Group 2 - REGEN is reportedly continuing its production and sales activities as per the established plan [1].

Group 1 - The beauty and personal care sector has shown a recovery in 2025, with the SW Beauty Index rebounding after a decline from 2022 to 2024, achieving a maximum increase of over 15% and becoming a key area in new consumption [3][9][10] - The cosmetics segment is characterized by intense competition among brands, with domestic brands making significant strides in R&D and distribution, while international brands are adopting localized strategies to regain market share [3][20][25] - The medical beauty market is transitioning from a blue ocean to a red ocean, with domestic companies expected to become major competitors by focusing on affordable and specialized products [3][19][24] Group 2 - The e-commerce operation sector is undergoing a transformation, with companies like RuYuchen and Shuiyang Co. leveraging brand incubation and AI to create new growth avenues [3][19] - Key investment recommendations include domestic brands with strong channel and brand matrices such as MaoGePing, ShangMei Co., and PoLaiYa, as well as companies in the medical beauty sector like AiMeiKe and LongZi Co. [3][19][24] - The report emphasizes the importance of brand matrix construction and product innovation in the cosmetics industry, with companies like ShangMei Co. and PoLaiYa leading the way [3][31][40] Group 3 - The skincare and makeup market is expected to enter a phase of consolidation, with strong brands likely to thrive while weaker ones may struggle [23][24] - The market share of domestic brands is increasing, with a notable decline in the market share of international brands, indicating a significant opportunity for domestic players [25][30] - The report highlights the importance of adapting to changing consumer preferences and channel dynamics, with a focus on online platforms and promotional strategies to enhance brand visibility [48][52][53]

Core Viewpoint - 九州通 is expanding its medical beauty business by acquiring control of the listed medical beauty company, 奥园美谷, which has entered a restructuring process [1][3]. Group 1: Investment and Restructuring - 九州通 announced its investment of 6.73 billion yuan to acquire 360 million shares of 奥园美谷, later adjusting the investment to 7.06 billion yuan for 436 million shares [1][3]. - 奥园美谷 has been in financial distress since 2020, leading to continuous losses and a "delisting risk warning" in 2023, with its stock renamed to "*ST美谷" [2]. - As of January 3, 2025, 奥园美谷 received interest from 45 potential investors, including 14 with industry-related backgrounds, despite its debt crisis [2]. Group 2: Strategic Advantages - 九州通 has established a strong presence in the medical beauty sector, having invested in key players and formed strategic partnerships since 2016 [5]. - The company’s medical beauty segment has seen a compound annual growth rate of 111.64% from 2022 to 2024, with sales revenue reaching 9.04 billion yuan in the first three quarters of 2025, a year-on-year increase of 45.84% [6]. - 九州通's medical beauty business leverages a comprehensive supply chain, advanced digital capabilities, and a wide network of over 11,538 medical beauty service institutions across 31 provinces [6]. Group 3: Future Prospects - 九州通 aims to enhance its competitive edge in the beauty and health industry through collaboration with 奥园美谷, focusing on supply chain integration and core product development [6]. - The restructuring investment is expected to positively impact 九州通's medical beauty operations, aligning with its long-term strategic development goals [3].

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Views - In Q3 2025, the company achieved operating revenue of 566 million yuan, a year-on-year decrease of 21.27%. The net profit attributable to the parent company was 304 million yuan, down 34.61% year-on-year, while the net profit excluding non-recurring items was 255 million yuan, a decline of 42.37% year-on-year [2][6]. - The revenue decline has narrowed sequentially due to the consolidation of REGEN Company, with revenue declines in Q1, Q2, and Q3 being 17.9%, 25.11%, and 21.27% respectively. The main reason for the narrowing decline is the lower revenue base starting from Q3 of the previous year [11]. - The company's gross profit margin for Q3 was 93.2%, a year-on-year decrease of 1.4 percentage points, while the net profit margin attributable to the parent company was 53.7%, down 11 percentage points year-on-year. This decline in profitability is attributed to revenue pressure and relatively rigid expense inputs [11]. - The internationalization strategy is expected to bring new growth. The consolidation of REGEN has introduced products that complement the existing product matrix, enhancing the company's offerings in the aesthetic medicine sector [11]. - The company forecasts EPS for 2025, 2026, and 2027 to be 4.92 yuan, 5.62 yuan, and 6.20 yuan respectively, indicating a positive outlook despite current pressures [11]. Financial Summary - For 2025, the company expects total revenue of 2.515 billion yuan, with a gross profit of 2.345 billion yuan, resulting in a gross margin of 93% [17]. - The projected net profit for 2025 is 1.489 billion yuan, with an EPS of 4.92 yuan [17]. - The company’s cash flow from operating activities is expected to be 1.499 billion yuan in 2025 [17].

Group 1 - The medical beauty sector experienced a decline of 1.28% on November 17, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] - Major stocks in the medical beauty sector showed varying declines, with Huaxi Biological down 1.04%, Aimeike down 1.05%, and Jinbo Biological down 1.96% [1] Group 2 - The net outflow of main funds in the medical beauty sector was 80.81 million yuan, while retail investors saw a net inflow of 56.06 million yuan [1] - Specific fund flows indicated that Huaxi Biological had a net outflow of 9.16 million yuan, *ST Meigu had a net outflow of 12.64 million yuan, and Aimeike had a net outflow of 59.00 million yuan [2]

| 2020-12-31 | | 2021-12-31 | 2022-12-31 | 2023-12-3 | | --- | --- | --- | --- | --- | | ■ 简军 | 261.7万 | 348.0万 | 250. 8万 | 251. 4万 | | -- 行业平均 186.9万 | | 223.6万 | 222.5万 | 188.6万 | 据东方财富网数据，爱美客董事长简军2024年所获薪酬为249万元，相较上年薪酬251.4万元微降。 瑞财经 钟鸣辰爱美客(SZ300896)近日发布2025年三季报，前三季同比营收利润双降。 | | 本报告期 | 本报告期比上年同期 | 年初至井 20 | | | --- | --- | --- | --- | --- | | | | 增减 | | | | 文化收入(元) | 565,783, 495, 32 | -21.27% | 1.864.965.981.58 | -21,49% | | 归属于 面上公司股东 | 303.801.013.19 | -34.61% | 1.093.263.532.76 | -31.05% | | 的净利润(元) | ...

Group 1 - The A-share medical sector continues to adjust, with leading stocks like WuXi AppTec, United Imaging Healthcare, and Aimeike all dropping over 1%, while Tigermed and Furuide fell more than 4% [1] - The largest medical ETF in A-shares (512170) dropped nearly 2%, reaching a three-month low and breaching the six-month moving average, indicating potential large capital inflows during the dip [1] - The medical sector's performance is currently diverging from its valuation, with the medical ETF (512170) trading at a PE ratio of 33.5 times, which is still below 65% of its historical range over the past decade [3][4] Group 2 - The medical device sector showed significant revenue growth of 10.65% year-on-year in Q3 2025, with expectations for continued positive trends into Q4 2025 [3] - The CXO (Contract Research Organization) segment performed strongly, with Q3 2025 revenue up 10.93% and net profit attributable to shareholders up 47.90%, indicating a favorable outlook for the industry [3] - The medical ETF (512170) has a current scale of over 25.8 billion yuan, making it the largest medical ETF in the market, focusing on "medical devices + medical services" [6][7]

Investment Rating - The industry investment rating is "Positive" (maintained) [7] Core Insights - The 2025 Double Eleven e-commerce promotion concluded with a total online sales of 1,695 billion yuan, representing a 14.2% increase compared to 2024. Tmall led in overall e-commerce sales, while JD reported record high transaction volumes with a 40% increase in the number of orders and nearly 60% growth in order volume [3][26] - The jewelry sector performed exceptionally well, with gold products favored by younger consumers. The demand for gold has evolved from a singular focus on value preservation to a multifaceted need for cultural recognition and emotional value, indicating higher growth potential for aesthetically and culturally rich gold jewelry [3][29] - The beauty sector achieved a total GMV of 132.5 billion yuan, with skincare and fragrance/cosmetics sales reaching 99.1 billion yuan and 33.4 billion yuan, respectively. Domestic brands like Proya and Han Shu dominated the sales charts, showcasing the strength of local brands [3][32] - The integration of AI technology in retail is enhancing consumer experiences, creating a virtuous cycle among consumers, merchants, and platforms [3][42] Summary by Sections Retail Market Review - The retail industry index rose by 4.06% during the week of November 10-14, 2025, outperforming the Shanghai Composite Index, which fell by 0.18%. The retail sector ranked third among 31 primary industries [5][14] - The supermarket sector saw the highest increase, with a weekly growth of 7.09%, while the jewelry sector led the year-to-date performance with a 23.66% increase [18][21] Retail Insights: Double Eleven Promotion - The Double Eleven e-commerce event showed resilience in growth, with significant sales increases across platforms. Tmall's comprehensive e-commerce sales reached 16,191 billion yuan, while instant retail sales soared by 138.4% [26] - Gold jewelry sales saw a remarkable increase, with the flagship store of Lao Pu Gold achieving over 3 billion yuan in sales within 10 minutes of opening on Tmall [29] - The beauty category's GMV reached 132.5 billion yuan, with domestic brands capturing significant market share, particularly in skincare and cosmetics [32] Focus on High-Growth Sectors - Investment recommendations include focusing on high-quality companies in sectors driven by emotional consumption themes, such as gold jewelry, offline retail, cosmetics, and medical aesthetics [6][48] - Specific companies highlighted for investment include Lao Pu Gold, Proya, and Aimeike, among others, which are expected to benefit from current market trends [49]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The retail sector shows a steady recovery in consumer spending, with a year-on-year increase of 4.3% in retail sales from January to October 2025, and a 2.9% increase in October alone [5] - Key categories such as essential goods like grains and oils maintain resilience, while discretionary items like gold and jewelry show remarkable performance, with jewelry sales up by 37.6% year-on-year in October [6] - Online retail continues to grow, with a 9.6% increase in online sales from January to October 2025, while offline retail channels also show signs of recovery [7] Summary by Sections Industry Overview - The retail sector is experiencing a robust recovery, with October retail sales reaching 46,291 billion yuan, exceeding market expectations [5] - The overall consumer price index (CPI) has turned positive, driven by rising prices in services and industrial goods [6] Consumer Behavior - Essential consumption categories like grains and oils have shown strong growth, while discretionary spending on cosmetics and jewelry has surged, indicating a shift towards "emotional consumption" [6][8] - The report emphasizes the importance of brands that resonate with consumers' emotional values and competitive strengths [8] Investment Recommendations - Focus on high-quality companies in the "emotional consumption" theme, particularly in four key areas: 1. Gold and jewelry brands with unique product offerings [8] 2. Offline retail companies adapting to market changes [8] 3. Domestic cosmetic brands emphasizing emotional value and safety [8] 4. Medical beauty firms with differentiated products and expansion strategies [8]